A Multi-center, Randomized, Double-blind, Placebo and Active Controlled, Parallel Group Study to Evaluate the Dose Response of AHU377 in Combination With Valsartan 320 mg After 8 Week Treatment in Patients With Mild-to-moderate Systolic Hypertension.

Trial Profile

A Multi-center, Randomized, Double-blind, Placebo and Active Controlled, Parallel Group Study to Evaluate the Dose Response of AHU377 in Combination With Valsartan 320 mg After 8 Week Treatment in Patients With Mild-to-moderate Systolic Hypertension.

Completed
Phase of Trial: Phase II

Latest Information Update: 05 Mar 2018

At a glance

  • Drugs Sacubitril (Primary) ; Sacubitril/valsartan; Valsartan
  • Indications Essential hypertension
  • Focus Therapeutic Use
  • Acronyms RATIO
  • Sponsors Novartis; Novartis Pharmaceuticals
  • Most Recent Events

    • 01 Dec 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 17 Oct 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 28 Jan 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top